Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. (PLSE) on October 6, 2021, covering events that occurred on October 4, 2021. The filing addresses significant changes to the Company's Board of Directors and executive officer designations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignations: Kenneth A. Clark resigned from the Board and all committees effective immediately for personal reasons. The resignation was not due to any disagreement with the Company. Mahkam Zanganeh, DDS, resigned from the Audit Committee but remains on the Board.
- Director Election: Laureen DeBuono was elected to the Board to fill the vacancy left by Mr. Clark. She was appointed to the Audit Committee and named Chair of the Nominating and Corporate Governance Committee.
- Officer Appointment: Mr. Levinson, previously Chief Strategy Officer, was designated as an executive officer under Exchange Act rules.
Compensation and Equity Arrangements
Ms. DeBuono's compensation includes an annual retainer of $40,000 for Board service, $10,000 for Audit Committee service, and $10,000 for Chairing the Nominating Committee. She received an initial stock option grant for 32,500 shares, with one-third vesting after one year and the remainder vesting monthly over two years. She is also eligible for annual grants of 20,000 shares. Mr. Clark's resignation included a waiver of the requirement to exercise his 150,574 vested options within 90 days.
Outlook, Risks, and Contingencies
The filing states that the departures were for personal reasons and not the result of disagreements regarding operations, policies, or practices. No specific financial risks, contingencies, or forward-looking guidance were disclosed in this document.
Key Facts for Investor Verification
- Verify the impact of the Board composition changes on the Company's strategic direction and audit oversight.
- Review the vesting schedule and dilution impact of the 32,500 initial option grant to Ms. DeBuono and potential future annual grants.
- Confirm the status of Mr. Clark's 150,574 vested options following the waiver of the 90-day exercise requirement.
- Check subsequent filings for any financial updates or strategic announcements related to the new Board leadership.